BE2017C049I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C049I2
BE2017C049I2 BE2017C049C BE2017C049C BE2017C049I2 BE 2017C049 I2 BE2017C049 I2 BE 2017C049I2 BE 2017C049 C BE2017C049 C BE 2017C049C BE 2017C049 C BE2017C049 C BE 2017C049C BE 2017C049 I2 BE2017C049 I2 BE 2017C049I2
Authority
BE
Belgium
Application number
BE2017C049C
Other languages
French (fr)
Original Assignee
Wyeth Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc
Publication of BE2017C049I2 publication Critical patent/BE2017C049I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
BE2017C049C 2002-05-02 2017-11-16 BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02
EP03724432.4A EP1507556B1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Publications (1)

Publication Number Publication Date
BE2017C049I2 true BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-08-09

Family

ID=29401497

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C049C BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-05-02 2017-11-16

Country Status (33)

Country Link
US (6) US8153768B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2371392B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP5153057B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR101062628B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100482277C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2003231293A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BRPI0309868B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2871117A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (3) CR7557A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1116634T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK2371392T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045445A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2545745T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HUE027590T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL164946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT3127553T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04010792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300903I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339730B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ586071A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH12013501159A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (5) PL224001B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT1507556T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2422157C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (3) SG187991A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI3127553T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI438010B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA88599C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003092623A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA200409752B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
SG187991A1 (en) * 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
EP1759582B1 (en) * 2004-05-26 2016-11-23 National University Corporation Kagawa University Preservative solution for cells, tissues and organs comprising rare sugar and preservation method with the use of the same
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
RU2007108716A (ru) * 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
JP2009504740A (ja) 2005-08-16 2009-02-05 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）製剤
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5806444B2 (ja) * 2005-12-02 2015-11-10 ノバルティス アーゲー 免疫原性組成物で使用するためのナノ粒子
US20070160577A1 (en) * 2005-12-06 2007-07-12 Wyeth Interleukin-11 compositions and methods of use
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
ATE521366T1 (de) * 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
CN104878064A (zh) 2006-07-13 2015-09-02 惠氏公司 糖蛋白的产生
NZ575350A (en) 2006-08-21 2012-02-24 Synta Pharmaceuticals Corp Bis(phenylcarbonothioyl)hydrazide derivatives
MX2009003542A (es) * 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
US8192951B2 (en) * 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
US8552067B2 (en) * 2006-12-22 2013-10-08 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor
CN101687916A (zh) * 2007-01-16 2010-03-31 惠氏公司 通过trem-1的炎症治疗、检测和监控
AU2008223133A1 (en) * 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
PT2155258T (pt) * 2007-05-22 2017-10-18 Wyeth Llc Processos melhorados para fabricar hidrazidas
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
EP2211904B1 (en) * 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
CA2707791A1 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
DK2238168T3 (da) * 2007-12-26 2014-08-25 Biotest Ag Midler, der er målrettet mod cd138 og anvendelser deraf
JP5817034B2 (ja) * 2007-12-26 2015-11-18 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体及びその使用
CN101945892B (zh) * 2007-12-26 2017-11-24 生物测试股份公司 用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
US8591889B2 (en) * 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
FR2930443B1 (fr) * 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
HUE043645T2 (hu) * 2009-06-03 2019-08-28 Immunogen Inc Konjugációs módszerek
US20130012916A1 (en) * 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
ES2862955T5 (en) 2010-10-01 2025-01-29 Modernatx Inc Engineered nucleic acids and methods of use thereof
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
US20120222979A1 (en) * 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
HUE041384T2 (hu) 2011-03-29 2019-05-28 Immunogen Inc Maytansinoid-antitest konjugátumok elõállítása egylépéses eljárással
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
MY163296A (en) 2011-08-30 2017-09-15 Astex Pharmaceuticals Inc Drug formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA2852021C (en) 2011-10-21 2018-08-28 Pfizer Inc. Addition of iron to improve cell culture
MX358680B (es) 2011-12-08 2018-08-31 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
RU2668159C2 (ru) 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN109200290A (zh) 2012-10-04 2019-01-15 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
US11193111B2 (en) 2013-01-17 2021-12-07 Case Western Reserve University Viral nanoparticle multimers
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2693370T3 (es) * 2013-05-02 2018-12-11 F. Hoffmann-La Roche Ag Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
RU2640197C1 (ru) * 2013-11-04 2017-12-27 Пфайзер Инк. Промежуточные соединения и способы синтеза производных калихеамицина
CA2929525A1 (en) 2013-11-04 2015-05-07 Pfizer Inc. Anti-efna4 antibody-drug conjugates
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
CN106661124A (zh) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
CN107001428B (zh) 2014-11-07 2023-01-10 卡斯西部储备大学 使用病毒颗粒的癌症免疫疗法
AU2016246737B2 (en) 2015-04-07 2019-11-21 Cornell University Nanoparticle immunoconjugates
EA201792312A1 (ru) * 2015-04-21 2018-06-29 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Конструкции на основе калихеамицина и способы их применения
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
WO2017004123A1 (en) 2015-06-29 2017-01-05 Case Western Reserve University Anticancer drug-containing plant virus particles
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP3725332B1 (en) * 2015-07-16 2023-10-04 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
WO2017172907A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
PL3440190T3 (pl) 2016-04-05 2024-12-02 Pfizer Inc. Sposób hodowli komórkowej
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
US11433123B2 (en) 2016-07-21 2022-09-06 Case Western Reserve University Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
WO2018085658A1 (en) 2016-11-03 2018-05-11 Case Western Reserve University Melt processed viral nanoparticle constructs
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
US20200255785A1 (en) 2017-09-15 2020-08-13 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
JP7462566B2 (ja) 2018-03-16 2024-04-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
SMT202100368T1 (it) * 2018-05-30 2021-07-12 Abbvie Stemcentrx Llc Coniugati anticorpo-farmaco anti-sez6 e metodi di utilizzo
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
MX2021005808A (es) 2018-11-20 2021-07-02 Univ Cornell Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
JP2022513702A (ja) 2018-12-06 2022-02-09 ファイザー・インク 阻害剤産生が低下した細胞およびその使用方法
CA3127142A1 (en) * 2019-02-13 2020-08-20 Coimmune, Inc. Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
TW202102542A (zh) 2019-03-19 2021-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的聯合療法
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CA3146379A1 (en) * 2019-07-08 2021-01-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
US20230071019A1 (en) * 2019-12-04 2023-03-09 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
KR20240139082A (ko) 2022-02-02 2024-09-20 화이자 인코포레이티드 시스테인 프로토트로피
JPWO2024058201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2022-09-16 2024-03-21
KR20250089547A (ko) 2022-10-25 2025-06-18 펩토믹, 에스.엘. 암 치료를 위한 조합 요법
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
WO2025063789A1 (ko) * 2023-09-21 2025-03-27 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE207075T1 (de) 1990-06-27 2001-11-15 Univ Princeton Sonden für die detektion der p53 mutante
EP1362868A3 (en) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
CN1172502A (zh) 1994-08-12 1998-02-04 亿万遗传股份有限公司 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
JP2002501488A (ja) 1997-03-20 2002-01-15 アメリカ合衆国 Ｃｄ２２を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
JP4562286B2 (ja) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
EP2289551A1 (en) * 1999-06-09 2011-03-02 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE60009926T2 (de) * 1999-08-17 2005-04-07 Novo Nordisk Health Care Ag Stabilisierung von gefriergetrocknetem kuchen
TR200201006T2 (tr) * 1999-10-12 2002-11-21 Connex Gesellschaft Zur Optimierung Von Forschung Und Dışkıda bulunan aside dirençli mikroorganizmaların tespitine ilişkin geliştirilmiş yöntem.
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates

Also Published As

Publication number Publication date
AU2009202609A1 (en) 2009-07-16
LUC00044I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-11-03
NL300903I2 (nl) 2018-02-08
PL228741B1 (pl) 2018-05-30
TW201231089A (en) 2012-08-01
CR7557A (es) 2008-10-03
NO20161431A1 (no) 2005-01-25
PT3127553T (pt) 2022-01-24
US8153768B2 (en) 2012-04-10
PH12013501158B1 (en) 2015-11-09
JP2012051900A (ja) 2012-03-15
HUS1700038I1 (hu) 2017-11-28
US20140235835A1 (en) 2014-08-21
PT2371392E (pt) 2015-10-07
BR0309868A (pt) 2005-10-18
PL222725B1 (pl) 2016-08-31
EP1507556A2 (en) 2005-02-23
ES2593304T3 (es) 2016-12-07
US9351986B2 (en) 2016-05-31
PL374523A1 (en) 2005-10-31
PH12013501158A1 (en) 2015-11-09
RU2011108928A (ru) 2012-09-20
AU2009202609B2 (en) 2012-07-26
PL224150B1 (pl) 2016-11-30
EP1507556A4 (en) 2009-01-07
JP5756489B2 (ja) 2015-07-29
SG165158A1 (en) 2010-10-28
EP3127553B1 (en) 2021-12-01
SG187991A1 (en) 2013-03-28
IL164946A0 (en) 2005-12-18
ES2916174T3 (es) 2022-06-28
KR20050006220A (ko) 2005-01-15
CY2017035I2 (el) 2018-04-04
NO339730B1 (no) 2017-01-23
RU2016141576A (ru) 2018-05-03
BRPI0309868B1 (pt) 2020-04-28
LTPA2017036I1 (lt) 2017-11-27
PH12013501159B1 (en) 2015-12-02
CN100482277C (zh) 2009-04-29
HUE027590T2 (hu) 2016-11-28
KR101125524B1 (ko) 2012-03-22
JP6872376B2 (ja) 2021-05-19
NZ586071A (en) 2012-02-24
DK1507556T3 (en) 2016-09-12
CY2017035I1 (el) 2018-04-04
NO2017061I1 (no) 2017-11-21
PT1507556T (pt) 2016-09-28
RU2422157C2 (ru) 2011-06-27
CN1665532A (zh) 2005-09-07
HK1070825A1 (en) 2005-06-30
LT3127553T (lt) 2022-04-11
CR20130390A (es) 2013-11-08
PL410219A1 (pl) 2015-03-30
IL164946A (en) 2015-06-30
PL413302A1 (pl) 2016-05-23
US8747857B2 (en) 2014-06-10
HUE030806T2 (hu) 2017-05-29
EP1507556B1 (en) 2016-07-27
SI3127553T1 (sl) 2022-02-28
LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-26
DK2371392T3 (en) 2015-08-31
HUE057124T4 (hu) 2022-02-28
FR17C1054I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-12
HUE057124T2 (hu) 2022-04-28
EP3127553A1 (en) 2017-02-08
DK3127553T3 (da) 2022-01-31
UA88599C2 (ru) 2009-11-10
ES2545745T3 (es) 2015-09-15
EP2371392B1 (en) 2015-07-08
NZ573563A (en) 2010-10-29
BR122019027966B1 (pt) 2020-11-17
RU2016141576A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-03
ZA200409752B (en) 2010-08-25
BRPI0309868B8 (pt) 2021-05-25
IL230659A0 (en) 2014-03-31
RU2422157C3 (ru) 2021-04-23
CA2483552A1 (en) 2003-11-13
PH12013501159A1 (en) 2015-12-02
CR20120364A (es) 2012-10-05
RU2602878C3 (ru) 2021-11-24
TWI379693B (en) 2012-12-21
CY1117973T1 (el) 2017-05-17
JP2005524700A (ja) 2005-08-18
PL224844B1 (pl) 2017-02-28
TW200404005A (en) 2004-03-16
ECSP045445A (es) 2005-01-28
US20180339058A1 (en) 2018-11-29
PL411824A1 (pl) 2015-08-17
TWI438010B (zh) 2014-05-21
EP2371392A1 (en) 2011-10-05
US20120213804A1 (en) 2012-08-23
PL410218A1 (pl) 2015-03-30
US20040192900A1 (en) 2004-09-30
ZA201003874B (en) 2019-12-18
US20040082764A1 (en) 2004-04-29
BR122019027966B8 (pt) 2021-07-27
WO2003092623A3 (en) 2004-03-18
JP5153057B2 (ja) 2013-02-27
JP2013163678A (ja) 2013-08-22
LT1507556T (lt) 2016-10-10
SI1507556T1 (sl) 2016-10-28
JP2017105801A (ja) 2017-06-15
NO344509B1 (no) 2020-01-20
WO2003092623A2 (en) 2003-11-13
CY1116634T1 (el) 2017-03-15
US8835611B2 (en) 2014-09-16
RU2004135101A (ru) 2005-06-27
CY1124900T1 (el) 2023-01-05
MXPA04010792A (es) 2005-03-07
JP5441971B2 (ja) 2014-03-12
SI2371392T1 (sl) 2015-10-30
AU2003231293A1 (en) 2003-11-17
NO20044663L (no) 2005-01-25
KR20110050753A (ko) 2011-05-16
IL230659A (en) 2016-02-29
HK1162926A1 (en) 2012-09-07
US20160303252A1 (en) 2016-10-20
RU2602878C2 (ru) 2016-11-20
CA2871117A1 (en) 2003-11-13
SG10201700289RA (en) 2017-02-27
KR101062628B1 (ko) 2011-09-07
BR122019027974B1 (pt) 2022-06-14
PL224001B1 (pl) 2016-11-30
FR17C1054I2 (fr) 2019-01-11
JP2015061875A (ja) 2015-04-02
LTC2371392I2 (lt) 2019-03-25
RU2678818C2 (ru) 2019-02-04

Similar Documents

Publication Publication Date Title
BE2019C547I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C510I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2018C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C005I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C040I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C013I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C078I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C002I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2018C018I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2013C039I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2013C025I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2011C038I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003198604A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN192749B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2013C046I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE60330807D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003056473A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE60333727D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU0202032D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003232859A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR0315835A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2002224360A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2003208898A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)